论文部分内容阅读
背景与目的:作者对河南食管癌高发区正常人和食管癌患者蛋白质组差异蛋白分析发现AnnexinⅡ是主要差异候选蛋白之一。本研究通过分析该地区食管鳞癌(esophageal squamous cell carcinoma,ESCC)及癌旁形态学正常食管上皮(normal epithelium,NOR)、基底细胞过度增生(basal cell hyperplasia,BCH)、不典型增生(dysplasia,DYS)和原位癌(carcinoma in situ,CIS)中AnnexinⅡ动态表达状况,探讨AnnexinⅡ在ESCC癌变过程中的作用及机制。方法:采用ABC免疫组织化学法分析了河南食管癌高发区33例ESCC手术标本和癌旁NOR,以及BCH、DYS和CIS中AnnexinⅡ蛋白表达变化;另应用RT-PCR方法检测了ESCC手术标本和癌旁NOR中AnnexinⅡ mRNA差异表达情况。结果:在90.6%的NOR中有AnnexinⅡ蛋白表达,免疫染色评分≥4,随着病变加重其表达下降,CIS时AnnexinⅡ蛋白完全失表达的比例达到了50.0%。高分化SCC时AnnexinⅡ蛋白表达又升高,而后随着SCC失分化表达逐渐降低,低分化SCC中45.4%病灶AnnexinⅡ失表达。但RT-PCR并没有检测到NOR和SCC中AnnexinⅡ mRNA的差异表达。结论:AnnexinⅡ表达增强或降低可能与癌前病变逆转或进展相关,并有可能成为高危人群筛查及食管癌早期诊断的分子指标。
BACKGROUND & OBJECTIVE: The authors analyzed proteome differences between normal and esophageal cancer patients in high incidence area of esophageal cancer in Henan Province, and found that AnnexinⅡ is one of the major differentially expressed proteins. In this study, we analyzed the relationship between esophageal squamous cell carcinoma (ESCC) and normal epithelium (NOR), basal cell hyperplasia (BCH), atypical hyperplasia (dysplasia, DYS and carcinoma in situ (CIS), and to explore the role of AnnexinⅡ in the carcinogenesis of ESCC. Methods: Immunohistochemical ABC method was used to analyze the changes of ESCC and NOR in 33 cases of ESCC and the expression of Annexin Ⅱ in BCH, DYS and CIS in Henan high incidence area. The other ESCC specimens Next to NOR in Annexin Ⅱ mRNA differential expression. Results: Annexin Ⅱ protein was expressed in 90.6% of NOR patients. The score of immunostaining was ≥4. The expression of Annexin Ⅱ protein decreased with the severity of disease. The percentage of Annexin Ⅱ protein lost completely in CIS was 50.0%. The expression of AnnexinⅡprotein increased after SCC differentiation, and then gradually decreased with the loss of differentiation of SCC. In poorly differentiated SCC, 45.4% of lesions showed no expression of AnnexinⅡ. However, RT-PCR did not detect the differential expression of AnnexinⅡ mRNA in NOR and SCC. CONCLUSION: The increase or decrease of Annexin Ⅱ expression may be related to the reversal or progression of precancerous lesions and may be the molecular marker of high risk population screening and early diagnosis of esophageal cancer.